{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T18:24:37Z","timestamp":1791829477029,"version":"4.3.4"},"reference-count":31,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T00:00:00Z","timestamp":1742774400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.cllc.2025.03.010","type":"journal-article","created":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T10:06:22Z","timestamp":1743156382000},"page":"324-330.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["The Toxicity Profile of Pemetrexed in Non-Small Cell Lung Cancer Patients With Moderate Renal Impairment: A Retrospective Cohort Study"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5321-0816","authenticated-orcid":false,"given":"Mart P.","family":"Kicken","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"ter Heine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Intissar","family":"Azarfane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikki","family":"de Rouw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenna","family":"de Vries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bas J.M.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nienke A.G.","family":"Lankheet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Eektimmerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Beerden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric J.F.","family":"Franssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisanne L.","family":"Krens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cor H.","family":"van der Leest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur A.J.","family":"Smit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert J.","family":"Polman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura C.","family":"Vermeer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W.G.","family":"van Putten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben E.E.M.","family":"van den Borne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel M.","family":"van den Heuvel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten J.","family":"Deenen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.cllc.2025.03.010_bib0001","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.2165\/11202640-000000000-00000","article-title":"Pemetrexed: a review of its use in the management of advanced non-squamous non-small cell lung cancer","volume":"69","author":"Baldwin","year":"2009","journal-title":"Drugs"},{"key":"10.1016\/j.cllc.2025.03.010_bib0002","unstructured":"FDA. Food and Drug Administration - ALIMTA (pemetrexed disodium) injection - product information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/021462s021lbl.pdf, 2024 (Accessed December 5, 2024)."},{"key":"10.1016\/j.cllc.2025.03.010_bib0003","unstructured":"EMA. European Medicines Agency - ALIMTA (INN-pemetrexed) - product information (EPAR). https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/alimta-epar-product-information_en.pdf, 2022 (Accessed December 5, 2024)."},{"issue":"22","key":"10.1016\/j.cllc.2025.03.010_bib0004","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2025.03.010_bib0005","doi-asserted-by":"crossref","first-page":"787","DOI":"10.3332\/ecancer.2017.787","article-title":"Non-small cell lung cancer treatment (r) evolution: ten years of advances and more to come","volume":"11","author":"Toschi","year":"2017","journal-title":"Ecancermedicalscience"},{"issue":"5","key":"10.1016\/j.cllc.2025.03.010_bib0006","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1007\/s002800050992","article-title":"A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation","volume":"44","author":"Rinaldi","year":"1999","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"10.1016\/j.cllc.2025.03.010_bib0007","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s00280-005-0036-1","article-title":"Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patients","volume":"57","author":"Latz","year":"2006","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"10.1016\/j.cllc.2025.03.010_bib0008","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s002800000144","article-title":"Population pharmacokinetics of pemetrexed disodium (ALIMTA) in patients with cancer","volume":"46","author":"Ouellet","year":"2000","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.cllc.2025.03.010_bib0009","unstructured":"ALIMTA. ALIMTA EPAR - Product information. 2023. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/alimta-epar-product-information_en.pdf."},{"issue":"9","key":"10.1016\/j.cllc.2025.03.010_bib0010","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1200\/JCO.2004.08.163","article-title":"Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy","volume":"22","author":"Hanna","year":"2004","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.cllc.2025.03.010_bib0011","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1200\/JCO.2007.15.0375","article-title":"Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer","volume":"26","author":"Scagliotti","year":"2008","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.cllc.2025.03.010_bib0012","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.cllc.2025.03.010_bib0013","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s00280-016-3078-7","article-title":"Effect of renal function on pemetrexed-induced haematotoxicity","volume":"78","author":"Ando","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.cllc.2025.03.010_bib0014","doi-asserted-by":"crossref","first-page":"S455","DOI":"10.1097\/01.JTO.0000283390.06980.49","article-title":"Correlation of pemetrexed (PEM) NSCLC exposure-response relationships (ERRs) to clinical study results from western and Japanese patient populations: PD4-3-4","volume":"2","author":"Latz","year":"2007","journal-title":"J Thorac Oncol"},{"issue":"4","key":"10.1016\/j.cllc.2025.03.010_bib0015","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/s00280-005-0077-5","article-title":"A semimechanistic-physiologic population pharmacokinetic\/pharmacodynamic model for neutropenia following pemetrexed therapy","volume":"57","author":"Latz","year":"2006","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"10.1016\/j.cllc.2025.03.010_bib0016","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00280-005-0035-2","article-title":"Clinical application of a semimechanistic-physiologic population PK\/PD model for neutropenia following pemetrexed therapy","volume":"57","author":"Latz","year":"2006","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.cllc.2025.03.010_bib0017","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.lungcan.2020.05.022","article-title":"Cumulative pemetrexed dose increases the risk of nephrotoxicity","volume":"146","author":"de Rouw","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2025.03.010_bib0018","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ejca.2019.08.012","article-title":"Pemetrexed exposure predicts toxicity in advanced non-small-cell lung cancer: a prospective cohort study","volume":"121","author":"Visser","year":"2019","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.cllc.2025.03.010_bib0019","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1200\/JCO.2004.00.9720","article-title":"Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function","volume":"24","author":"Mita","year":"2006","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.cllc.2025.03.010_bib0020","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1002\/ijc.33721","article-title":"Toxicity of pemetrexed during renal impairment explained-implications for safe treatment","volume":"149","author":"Boosman","year":"2021","journal-title":"Int J Cancer"},{"key":"10.1016\/j.cllc.2025.03.010_bib0021","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.lungcan.2019.06.012","article-title":"Real-world prevalence of programmed death ligand 1 expression in locally advanced or metastatic non-small-cell lung cancer: the global, multicenter EXPRESS study","volume":"134","author":"Dietel","year":"2019","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.cllc.2025.03.010_bib0022","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s00408-008-9123-5","article-title":"Lung cancer and renal insufficiency: prevalence and anticancer drug issues","volume":"187","author":"Launay-Vacher","year":"2009","journal-title":"Lung"},{"key":"10.1016\/j.cllc.2025.03.010_bib0023","unstructured":"Santeon. Santeon Ziekenhuizen. https:\/\/santeon.nl\/over-santeon\/ziekenhuizen\/, 2024 (Accessed December 5, 2024)."},{"issue":"9","key":"10.1016\/j.cllc.2025.03.010_bib0024","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.cllc.2025.03.010_bib0025","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1373\/clinchem.2006.077180","article-title":"Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values","volume":"53","author":"Levey","year":"2007","journal-title":"Clin Chem"},{"issue":"1","key":"10.1016\/j.cllc.2025.03.010_bib0026","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"10.1016\/j.cllc.2025.03.010_bib0027","series-title":"Mosby's diagnostic & laboratory test reference","author":"Pagana","year":"2021"},{"issue":"4","key":"10.1016\/j.cllc.2025.03.010_bib0029","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.annonc.2022.12.013","article-title":"Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.cllc.2025.03.010_bib0030","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.cllc.2023.12.011","article-title":"Pembrolizumab plus chemotherapy per PD-L1 stratum In patients with metastatic non-small cell lung cancer: real-world effectiveness versus trial efficacy","volume":"25","author":"Verschueren","year":"2024","journal-title":"Clin Lung Cancer"},{"issue":"1","key":"10.1016\/j.cllc.2025.03.010_bib0031","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ejca.2006.11.004","article-title":"International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency","volume":"43","author":"Lichtman","year":"2007","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.cllc.2025.03.010_bib0032","first-page":"103","article-title":"Adjusted dosing and schedule of Pemetrexed in impaired renal function","volume":"6","author":"Ohana","year":"2016","journal-title":"J Hematol Oncol Pharm"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730425000567?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730425000567?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T15:26:11Z","timestamp":1747754771000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730425000567"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S1525730425000567"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2025.03.010","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Toxicity Profile of Pemetrexed in Non-Small Cell Lung Cancer Patients With Moderate Renal Impairment: A Retrospective Cohort Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2025.03.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}